Spectrum Pharmaceuticals Given “Positive” Rating at Roth Capital (SPPI)
Several other analysts have also recently commented on the stock. Analysts at Zacks downgraded shares of Spectrum Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Thursday, June 5th. They now have a $8.60 price target on the stock. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $11.72.
Shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) opened at 8.90 on Monday. Spectrum Pharmaceuticals has a 1-year low of $6.36 and a 1-year high of $10.32. The stock has a 50-day moving average of $8.09 and a 200-day moving average of $8.07. The company’s market cap is $564.7 million.
Spectrum Pharmaceuticals (NASDAQ:SPPI) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.01 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.22) by $0.23. The company had revenue of $40.10 million for the quarter, compared to the consensus estimate of $39.49 million. During the same quarter last year, the company posted $0.01 earnings per share. The company’s revenue for the quarter was up 3.6% on a year-over-year basis. Analysts expect that Spectrum Pharmaceuticals will post $-0.70 EPS for the current fiscal year.
Spectrum Pharmaceuticals, Inc (NASDAQ:SPPI) is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.